[ad_1]
Health Secretary Matt Hanbad revealed that the UK is planning a next five-year plan to address the growing threat of antimicrobial resistance, which would claim at least 700,000 deaths a year worldwide.
At the heart of this plan is the development of a new method of payment for antibiotics that he believes will be developed in the NHS over the next six months.
Hanbad announced the 2019-2024 plan – the next step in the UK's 20-year vision of a world in which RAM would be "controlled and controlled" by 2040 – at the World Economic Forum from Davos, where he said that AMR was "as great a danger as climate change or war … and requires an urgent global response."
The key elements of the plan are to reduce the burden of infection by improving the treatment of resistant organisms and reducing transmission, ensuring that drugs are used in the best possible way to discourage the development of resistance. encouraging the development of new treatment and treatment products. diagnose infections.
Key elements of the five-year strategy include incentives for pharmaceutical companies to conduct R & D on new antimicrobial drugs – such as the £ 50 million funding provided by the UK GlobalAMR Fund for Innovation. (GAMRIF) – and the 15% reduction in the inappropriate use of antibiotics% in five years.
It also sets specific goals, including halving the number of Gram-negative blood flow infections badociated with health care, reducing the total number of specific drug-resistant infections by 10%. 39; here five years and the 25% reduction in the use of antibiotics in food producing animals, between 2016 and 2020.
"We're going to do that, both in humans and in the animal world, through vaccination, better infection control, working with doctors, veterinarians, farmers, and patients to improve the quality of life." 39; prevent the unnecessary prescription of antibiotics, "said Hanbad at a press conference in Davos.
Matt Hanbad, Secretary of Health
Pharma Incentive
There has been no new clbad of antibiotics since the 1980s, Hanbad continued, which is "shocking and deeply troubling". The solution is to develop a new business model for the development of antibiotics that does not link turnover to volume, as new anti-infectives must generally be retained.
In this case, the NHS could take the initiative to launch a new payment system reflecting the true value of antibiotics to society and transform the way these medicines are viewed from a product to a service, has it? he said, comparing the vinyl change to Spotify's subscribers. record shopper, with fees paid in advance.
"Within six months, the NHS will start paying for the service – and therefore the security – to have access to essential antibiotics when we need them, instead of hoping that there is a product we can buy in the future. "
The intention is also to try to encourage the adoption of this new funding model internationally, and Mr Hanbad said that he would meet with 39 other health ministers and pharmaceutical company executives in the coming weeks and months to try to encourage similar efforts beyond the UK.
The AMR represents a huge threat to health systems and is expected to kill about 10 million people every year by 2050, according to the 2016 O'Neill report commissioned by the British government.
<! –
->
Source link
